Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET
Company Participants
Jennifer Good - President and CEO
Lisa Delfini - CFO
Conference Call Participants
Annabel Samimy - Stifel
Serge Belanger - Needham & Company
Operator
Good afternoon, and welcome to the Trevi Therapeutics Q3 2022 Earnings Conference Call. [Operator Instructions] Please note, today's event is being recorded.
Various remarks that management makes during this conference call about the company's future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of the company's most recent quarterly report on Form 10-Q, which the company filed with the SEC this afternoon.
In addition, any forward-looking statements represent the company's views only as of today and should not be relied upon as representing the company's views as of any subsequent date. While the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so even if its views do change.
I would now like to turn the conference over to Jennifer Good, Trevi's President and CEO. Please go ahead.
Jennifer Good
Good afternoon, and thank you for joining our third quarter earnings call and business update. Joining me today on this call is Lisa Delfini, Trevi's Chief Financial Officer. Lisa and I have some short prepared remarks, then we will be available for questions at the end of the call.
This has been an exciting year for Trevi with regard to delivering against our business plans, and the third quarter was no exception. As expected, the full trial results for our CANAL trial in chronic cough and idiopathic pulmonary fibrosis, or IPF, were reported in September and confirmed the positive interim results previously reported, showing a significant reduction in the frequency of cough from baseline, and were highly statistically significant on both the primary and several key secondary endpoints. This included objective measures of coughs, patient-reported outcomes on cough frequency and severity, along with investigator-reported improvements in coughs.
In mid-September, we hosted an R&D Day to review these results in detail along with the PN results and heard from prominent KOLs and [indiscernible]. Instead of rereviewing all of the information, I would like to provide you with an update on our activities since our R&D Day. Chronic cough in IPF has emerged as our lead indication, and we are busy developing protocols for the next phase of development and interacting with both the FDA and preparing for interactions with European regulatory authorities. Haduvio is the lead therapy in development for cough and IPF and is the only one to have shown positive results in a blinded study in this indication. IPF is a serious end-of-life disease and chronic cough is a major cause of morbidity, significantly impacting the patient's quality of life.